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Background: In order to initiate a disease elimination programme for lymphatic filariasis based on mass drug
administration, a proper understanding of the geographical distribution and degree of risk is essential.
Methods: An investigation of lymphatic filariasis due to Wuchereria bancrofti was carried out among 785 people in
four communities of Yakurr Local Government Area of Cross River State, Nigeria between March and August, 2009.
Finger prick blood smear samples collected from the subjects were examined for W. bancrofti using standard
parasitological protocol. The subjects were also screened for clinical manifestations of lymphatic filariasis.
Results: Of the 785 persons examined, 48 (6.1%) were positive for microfilariae in their thick blood smear. There
was a significant difference in the prevalence of lymphatic filariasis among the various age groups (P < 0.01)
although peak prevalence occurred between 41 – 60 years. There was no significant difference in prevalence and
density with respect to sex (P> 0.05). The overall mean microfilarial density of the infected individuals was 5.6mf/50 μl.
There was a significant variation (P< 0.01) in mean microfilarial density within the communities, ranging from 4.7 to 6.4
mf/50 μl. The only clinical sign found in the study area was lymphoedema of the leg recording 2 (0.3%) prevalence.
Conclusions: The National Lymphatic Filariasis Elimination Programme should intervene by expanding the distribution
of albendazole and ivermectin to all endemic areas including Yakurr Local Government Area of Cross River State,
Nigeria.
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Lymphatic filariasis is a major public health problem,
affecting 120 million people living in 72 countries of
the world [1], 39 African countries carry over a third of
the global burden of lymphatic filariasis [1]. Lymphatic
filariasis is associated with dermatitis, elephantiasis and
hydrocoele [2]. Severe complications could include lym-
phoedema and elephantiasis of the limbs or genitalia,
which adversely affect personal and social life, and limit
occupational activities.
Filariasis is one of the most common causes of perman-
ent disability worldwide creating the highest disease bur-
den in terms of DALYs among tropical disease [3]. The
disease is a major cause of poverty as it leads to economic
burden for those affected, their dependants, their commu-
nities and their country as a whole [4,5]. Consequently, in* Correspondence: nkopara@yahoo.com
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reproduction in any medium, provided the or1998, the Global Alliance to Eliminate Lymphatic Filariasis
(GAELF) was formed to support the lymphatic elimi-
nation programme in endemic countries and The World
Health Organization launched a Global Programme to
Eliminate Lymphatic Filariasis (GPELF) [6], which has the
goal of eliminating the disease as a public health problem
by 2020. The strategy aimed at achieving this goal is
twofold. First, interrupt transmission of the LF parasite
by delivering single annual doses of diethylcarbamazine
(DEC) or ivermectin plus albendazole to the entire eligible
population living in areas where the disease is endemic
(defined as areas where the prevalence of microfilaraemia
or antigenaemia is ≥1%). In addition to interrupting
transmission, mass drug administration (MDA) provides
significant collateral health benefits, such as reduced mor-
bidity from intestinal worms and ectoparasites (for exam-
ple, lice). Second, alleviate suffering and disability by
introducing basic measures, such as improved hygiened. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ding surgery for men with hydrocele [7].
Available literature on the disease from both the North
and Central parts of Nigeria and the report of a postal
survey by the Nigerian Lymphatic Filariasis Elimination
Programme (NLFEP) have shown that lymphatic filariasis
is endemic [8-10]. One of the greatest challenges con-
fronting the NLFEP is the lack of information on the dis-
tribution and degree of risk of the disease in the country.
The NLFEP of the Federal Ministry of Health, with the
assistance of The Carter Centre has set 2015 as the year
to eliminate the disease in Nigeria. Even though a num-
ber of investigators [11-14] have carried out studies in
different parts of the country, there is need to collate
epidemiological data because most areas of the country
have not yet received attention
The main objective of this study was to investigate the
status of this infection amongst the Yakurr people of Cross
River State, Nigeria, prior to the launch of the lymphatic
filariasis elimination programme in Cross River Basin,
where annual mass administration of ivermectin has been




A preliminary survey of lymphatic filariasis caused by
W. bancrofti was carried out among the Yakurr people
of Cross River State, Nigeria. This area is situated between
latitude 5°400 and 6°N and longitude 7°550 and 8°330 E.
The communities randomly selected for the investigation
included; Idomi, Ijom, Lekpankom and Ntankpo. They are
The African Programme for Onchocerciasis Control
(APOC) Community Directed Treatment with Ivermectin
(CDTi) communities, and have been receiving treatment
since 1995. They have a therapeutic coverage of over
80%. The Yakurr people are mainly farmers cultivating
mainly yams, cassava and rice. This area is located in the
tropical rainforest belt with high annual rainfall, high rela-
tive humidity and high mean annual temperature [15].
Ethical consideration
Permission to conduct this survey was obtained from The
Centre for Clinical Governance Research and Training of
the Ministry of Health, Cross River State, Nigeria, beforeTable 1 Prevalence (%) and clinical manifestation of lymphat





Total 5,798 785(13.5)the commencement of the study. Consent was also ob-
tained from the Paramount Ruler and the respective
Community Heads of the Yakurr Local Government Area
where investigation was carried out. They were informed
of the nature, scope and purpose of the study. Peripheral
night blood collection from the subjects and inconve-
niences of pains on pricking the finger were explained.
Participation of individuals in these communities was
voluntary.
Sample collection
The sample for the present survey was drawn from house-
hold selected through systematic sampling with random
start, selecting every alternate household. Each selected
household was considered as a sampling unit as previously
described [14]. Participants from the various communities
were mobilized by the respective Community Heads to ga-
ther in their respective Community Health centre between
2300 and 0300 hours. Information about age, sex, history
of previous treatment with ivermectin were obtained from
each individual and recorded on a standard form. A total
of 785 finger prick blood samples were collected from the
four communities between March and August, 2009.
Parasitological examination
Giemsa stained thick blood smear was used for the iden-
tification of microfilariae using a binocular microscope.
Microfilariae of W. bancrofti were identified based on
specific morphological features and sizes as described
by Cheesbrough [16]. They were counted in each for
the infected morphological density and recorded on the
standard individual forms. The keys of Cheesbrough [16]
were used to identify and distinguish microfilariae of
W. bancrofti from microfilariae of other filarial worms,
Mansonella perstans and Loa loa
Clinical examination
Trained medical personnel recruited for this study exa-
mined all the 785 persons for clinical manifestation
of lymphatic filariasis. All males and females were exa-
mined for signs of the limb and breast elephantiasis.
Males had their genitals examined for hydrocoele and
scrotal elephantiasis. Clinical manifestations were staged
as described [17].ic filariasis due to W. bancrofti by community
Microfilaraemia positives Lymphoedema Positives
9 (4.1) 0 (0.0)
10 (6.6) 1 (0.7)
13 (5.8) 0 (0.0)
16 (8.5) 1 (0.5)
48 (6.1) 2 (0.3)





No (%) positive for
microfilariae of LF
1 – 20 36 9 (2.5)
21 – 40 184 16 (8.7)
41 – 60 157 19 (12.1)
61 – 80 79 4 (5.1)
Total 785 48 (6.1)
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The differences in the distribution of lymphatic filariasis
among communities and age groups were determined
using the analysis of variance (ANOVA). The prevalence
of infection between sexes, and age was determined by
chi-square test, while student ‘t’ test determined diffe-
rences in density. All data were analyzed using SPSS for
windows version 10.0 (SPSS Inc Chicago, IL).
Results
A total of 785 Yakurr people of Cross River State
were examined for lymphatic filariasis due to W. bancrofti.
Sampling coverage ranged from 11.1% to 18.4% between
the communities. It was observed that 48 (6.1%) out of
the 785 persons were infected (Table 1). The prevalence of
infection showed significant variation (P < 0.05) among
the communities ranging from 4.1% in Idomi to 8.5% in
Ntankpo (Table 1).
The prevalence of lymphatic filariasis by age is shown
in Table 2. There was a gradual increase in the disease
prevalence with age, reaching a peak in the 41 – 60 years
old age group before the decline (Table 2). There was
significant difference (P< 0.01) in the prevalence of lym-
phatic filariasis among the various age groups.
Of the 785 persons examined, 317 and 468 were males
and females respectively, and 18 (5.7%) and 30 (6.4%)
males and females were infected respectively (Table 3).
Although more females were infected than males, there
was no significant difference (P >0.05).
The microfilarial density indicated a mean overall
value of 5.6 mf/50 μl of blood, (Table 3). There was no
significant difference in the density of microfilaraemia
between males and females (P > 0.05) Table 3. There wasTable 3 Prevalence (%) and mean density of W. bancrofti infe
Community Total number of individuals examined Numbe
Male Female Male
Idomi 93 128 3 (3.2)
Ijom 64 87 4 (6.3)
Lekpankom 80 144 5 (6.3)
Ntankpo 80 109 6 (7.5)
Total 317 468 18 (5.7)a significant variation (P < 0.01) in microfilarial density
between the communities it ranged from 4.7mf/50 μl in
Lekpankom to 6.4mf/50 μl in Ijom.
The only clinical manifestation of lymphatic filariasis
due to W. bancrofti in the study population was lymphoe-
dema (Table 1). Out of the 785 persons examined, 2 (0.3%)
showed stage 2 lymphoedema of both legs. No other clini-
cal manifestation were encountered.
Discussions
This preliminary survey of lymphatic filariasis among
785 Yakurr people of Cross River State, Nigeria revealed
an overall prevalence of 48 (6.1%). This is consistent with
the results obtained by Udoidung et al. and Targema et al.
[14,18] who reported 6.5% and 5.5% in Benue State and
in some rural communities of the Lower Cross River
Basin, Nigeria respectively. Higher prevalence was found
in other studies of lymphatic filariasis due to W. bancrofti
in Nigeria. Work by Okon et al. [12] reported 15.5%
among Mbembe people of Cross River State, Anosike
et al. [19] reported 16.9% among the Ezza people of
Ebonyi State while Mbah and Njoku [20] observed 18.8%
in Aguata Local Government Area of Anambra State. The
lower prevalence in the present study could be due the
current Government effort of CDTi project where iver-
mectin is being distributed in some communities in the
Cross River State, including those of the Yakurr people.
Ivermectin has the ability to eliminate microfilariae of
other filarial parasites such as M. perstans and Loa loa
including W. bancrofti [21]. The potential benefit of over-
lapping interventions have recently been highlighted else-
where, and is an important consideration for determining
the risk of lymphatic filariasis in Nigeria [22].
This study indicated a gradual increase in prevalence
with increasing age range, thereafter there was a decline
at the age range of 61 – 80 years. The prevalence observed
among the 61 – 80 year age group may be due to resis-
tance to new infection resulting from acquired immunity.
However, a peak prevalence of 12.1% was recorded in the
41 – 60 year age group during this study. In a related
study, Anosike [11] observed a gradual increase in preva-
lence with increasing age and a peak prevalence at age
range of 40 – 49 years. In this study, the high prevalencection by community and sex
r (%) infected Mean microfilarial density mf/50 μl Total
mf/
50 μlFemale Male Female
6 (4.7) 6.0 6.5 6.3
6 (6.9) 6.5 6.3 6.4
8 (5.6) 4.4 5.0 4.7
10 (9.2) 4.0 5.3 4.8
30 (6.4) 5.2 5.8 5.6
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that these age groups are involved in intense occupational
activities such as farming and fishing. Typical Yakurr
farmers spend three-quarters of the daytime in outdoor
farming activities, hence they were exposed to more mos-
quito vectors in water pools prevailing in their cassava
farms and rice fields.
The prevalence rate for males and females were 18
(5.7%) and 30 (6.4%) respectively. There was no statisti-
cally significant difference between both sexes. Both men
and women engage equally in the activities that exposed
them to the vectors. They were also exposed to the same
living conditions. Most houses in the area had mud walls,
thatched roofs, no ceiling; hence permitting movement of
insects in and out as was earlier reported [14]. Also expo-
sure to various breeding sites of the vectors due to their
poor environmental and unhygienic conditions might have
accounted for the equal prevalence of both males and
females.
A mean microfilarial density of 5.6mf/50 μl of night
peripheral blood was found among the infected popula-
tion of Yakurr people of Cross River State, Nigeria. Okon
et al. [12] found a mean density of 9.9mf/50 μl among
the Mbembe people of Obubra Local Government Area
of Cross River State. While Anosike [11] found a mean
microfilarial density of 10.4mf per 20 mm3 of night peri-
pheral blood. Microfilarial density is an important index
in the epidemiology, treatment and control of human fi-
lariasis in endemic foci. The mean microfilarial density
of 5.6 mf/50 μl obtained in this study is lower than the
9.9mf/50 μl and 9mf/50 μl obtained by [12,14] respecti-
vely. In spite of the low microfilarial density in the study
area, there is a need for implementation of the various
control measures in this locality. The low parasite den-
sity might also be due to the ongoing CDTi in the area,
since the drug has an effect on W. bancrofti [21,23].
The only clinical manifestation of the lymphatic filariasis
infection was lymphoedema found in 2 (0.3%) of the entire
study population. This has been reported by several inves-
tigators as the cause of disability and disfigurement in en-
demic areas [24-26]. Hydrocele which is an important
clinical manifestation of lymphatic filariasis was not ob-
served in this study as was the case with previous inves-
tigations in the state [12,14]. The low prevalence of
lymphoedema and absence of hydrocele might be due
to human or parasite genetic differences or transmission
related factors [27].
Conclusions
This is the first documented report of lymphatic filariasis
among the Yakurr people of Cross River State, Nigeria.
This will thus enrich the epidemiological baseline data
of the disease in Nigeria. The Government should inter-
vene by expanding the distribution of albendazole inaddition to the CDTi that is presently going on in the com-
munities. Preventative chemotherapy and transmission
control (PCT) with albendazole and ivermectin annually in
populations at risk where lymphatic filariasis prevalence of
more than or equal to 1% is the basis of lymphatic filariasis
elimination programmes [28,29].
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